Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) a psychedelic drug company, has announced the speaker for the third webinar in its Psychedelics for Alcoholism series. The company has invited addiction specialist and world-renowned author Dr. Gabor Maté to talk on the effects of Alcohol Use Disorder, addition and trauma. The webinar will also include information about Clearmind’s patented portfolio as an effective treatment for the disorder. A retired Vancouver physician and a member of the Order of Canada, Maté has written several books with his most recent book — “The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture” — scheduled for publication this year. Other participants in the webinar include Clearmind CEO Adi Zuloff-Shani and Clearmind vice president of business development Mark Haden.
To attend the webinar, visit https://ibn.fm/Hkzcp
To view more information, visit https://ibn.fm/XDk3T
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of four patent families. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. For more information about the company, visit www.ClearmindMedicine.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
